Table 3 Clinical trials with CSF1/CSF1R inhibitors in combination with cancer immunotherapy agents
From: Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Class | Target | Compound/Class | Combination partner | Clinical phase | Sponsor | Indication | ClinicalTrials.gov identifier | Status/Results | Reference |
|---|---|---|---|---|---|---|---|---|---|
Small molecule | CSF1R (and cKIT, Flt3) | Pexidartinib (PLX3397, PLX108-01) | Pembrolizumab (anti-PD1 mAb) | 1/2 | Plexxikon/Daiichi Sankyo | Solid tumors, malignant melanoma GIST, NSCLC, ovarian carcinoma, TNBC, SCCHN, UBC, pancreatic cancer, gastric carcinoma, leiomyosarcoma, cholangio carcinoma, CRC (MSS) | NCT02452424 | Ongoing | [74] |
Durvalumab (anti-PDL1 mAb) | 1 | Astra Zeneca | Pancreatic carcinoma, CRC | NCT02777710 | Ongoing | - | |||
CSF1R | ARRY-382 | Pembrolizumab (anti-PD1 mAb) | 1 | Array BioPharma | Solid tumors, melanoma, NSCLC | NCT02880371 | Ongoing | - | |
CSF1R | BLZ945 | PDR001 (anti-PD1 mAb) | 1/2 | Novartis | Solid tumors | NCT02829723 | Ongoing | - | |
Monoclonal antibody | CSF1R | Emactuzumab (RG7155) | Atezolizumab (anti-PDL1 mAb) | 1 | Roche | Solid tumors, TNBC, gastric cancer, soft tissue sarcoma, UBC, ovarian cancer, NSCLC, melanoma | NCT02323191 | Ongoing | - |
RG7876 (CD40 agonist mAb) | 1 | Roche | TNBC, gastric cancer, mesothelioma, CRC, melanoma, pancreatic cancer | NCT02760797 | Ongoing | - | |||
CSF1R | AMG820 | Pembrolizumab (anti-PD1 mAb) | 1 | Amgen | Solid tumors | NCT02713529 | Ongoing | - | |
CSF1R | Cabiralizumab (FPA008) | Nivolumab (anti-PD1 mAb) | 1 | FivePrime/BMS | Solid tumors, NSCLC, SCCHN, pancreatic cancer, ovarian cancer, RCC, GBM | NCT02526017 | Ongoing | [75] | |
CSF1R | IMC-CS4 (LY3022855) | Durvalumab (anti-PDL1 mAb) or Tremelimumab (anti-CTLA4 mAb) | 1 | Eli Lilly | Solid tumors | NCT02718911 | Ongoing | [76] | |
CSF1 | MCS110 | PDR001 (anti-PD1 mAb) | 1/2 | Novartis | Solid tumors, TNBC, pancreatic cancer, melanoma, endometrial cancer | NCT02807844 | Ongoing | - | |
CSF1 | PD-0360324 | Avelumab (anti-PDL1 mAb) | 1 | Pfizer | Solid tumors | NCT02554812 | Ongoing | - |